Antifungal properties of the anti-hypertensive drug: aliskiren.

Archives of oral biology 20130901

The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes.

Diabetes care 20121101

The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension.

Expert opinion on pharmacotherapy 20121101

Incidence of angio-oedema associated with ARBs, ACE inhibitors, and aliskiren.

BMJ (Clinical research ed.) 20121017

In vitro controlled release of antihypertensive drugs intercalated into unmodified SBA-15 and MgO modified SBA-15 matrices.

International journal of pharmaceutics 20121015

Chronic direct renin inhibition with aliskiren prevents the development of hypertension in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent hypertension.

The American journal of the medical sciences 20121001

A validated LC method for the determination of the enantiomeric purity of aliskiren hemifumarate in bulk drug samples.

Journal of chromatographic science 20121001

AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.

American journal of physiology. Renal physiology 20121001

Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function.

Medical hypotheses 20121001

Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.

Clinical pharmacokinetics 20121001

Aliskiren reduces portal pressure and intrahepatic resistance in biliary cirrhotic rats.

Journal of the Chinese Medical Association : JCMA 20121001

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120901

Exploring the substructural space of indole-3-carboxamide derivatives binding to renin: a novel active-site spatial partitioning approach.

Journal of molecular modeling 20120901

Inhibition of renin activity slows down the progression of HIV-associated nephropathy.

American journal of physiology. Renal physiology 20120901

High glucose potentiates and renin-angiotensin blockade downregulates LPS-induced tissue factor expression in human mononuclear cells.

Thrombosis research 20120901

Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial.

International journal of clinical practice 20120901

[Is there still a place for a dual blockade of the renin-angiotensin system in 2012?].

Revue medicale suisse 20120829

Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis.

Clinical and experimental nephrology 20120801

How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?

Cellular signalling 20120801

Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.

Hypertension research : official journal of the Japanese Society of Hypertension 20120801

Renin inhibitor aliskiren exerts neuroprotection against amyloid beta-peptide toxicity in rat cortical neurons.

Neurochemistry international 20120801

Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (Aliskiren Alone or in Combination with Hydrochlorothiazide in Patients with Stage 2 Hypertension to Provide Quick Intensive Control of Blood Pressure [ACQUIRE] substudy).

Journal of clinical hypertension (Greenwich, Conn.) 20120801

Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients.

Journal of clinical hypertension (Greenwich, Conn.) 20120801

Rapid HILIC method with fluorescence detection using derivatization reaction utilizing o-phthaldialdehyde for determination of degradation product of aliskiren.

Journal of pharmaceutical and biomedical analysis 20120701

Vitamin D receptor signaling inhibits atherosclerosis in mice.

Molecular endocrinology (Baltimore, Md.) 20120701

Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview.

Expert opinion on drug safety 20120701

Early signals.

Prescrire international 20120701

Aliskiren: negative trial data.

Prescrire international 20120701

Amlodidine + aliskiren.

Prescrire international 20120701

Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.

Journal of medicinal chemistry 20120628

ACP Journal Club. Review: Aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone.

Annals of internal medicine 20120619

Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan.

Journal of pharmacological sciences 20120616

A new approach to the synthesis of peptidomimetic renin inhibitors: palladium-catalyzed asymmetric allylation of acyclic alkyl aryl ketones.

Organic letters 20120615

Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.

Regulatory peptides 20120610

Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.

International urology and nephrology 20120601

Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120601

Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease.

American journal of hypertension 20120601

Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.

Journal of cardiovascular pharmacology 20120601

Solid-state nuclear magnetic resonance study of the physical stability of electrospun drug and polymer solid solutions.

Journal of pharmaceutical sciences 20120601

Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120601

Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients.

European heart journal 20120601

Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy.

The Journal of pharmacy and pharmacology 20120601

An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 20120601

Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120512

[Chronic kidney disease (CKD)--recent progress. Topics: VII. Management of chronic kidney disease (CKD) and treatment; 2. Renoprotective effects of novel drugs].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20120510

Clinical role of direct renin inhibition in hypertension.

American journal of therapeutics 20120501

Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.

Journal of clinical pharmacology 20120501

Aliskiren reduces portal pressure in portal hypertensive rats.

European journal of clinical investigation 20120501

Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.

European journal of clinical pharmacology 20120501

Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study.

Journal of hypertension 20120501

RAS blockade, hyperkalemia and AKI--look and you will find.

Nature reviews. Nephrology 20120501

Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.

Journal of clinical hypertension (Greenwich, Conn.) 20120501

Failure to intensify hypertension therapy after rejected aliskiren claims.

Clinical therapeutics 20120501

Anti-fibrotic effect of Aliskiren in rats with deoxycorticosterone induced myocardial fibrosis and its potential mechanism.

Bosnian journal of basic medical sciences 20120501

Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus.

Diabetes, obesity & metabolism 20120401

Aliskiren-associated acute kidney injury in a patient with pre-existing chronic kidney disease and dilated cardiomyopathy.

Clinical and experimental nephrology 20120401

Aliskiren reduces portal pressure in cirrhotic rats.

Liver international : official journal of the International Association for the Study of the Liver 20120401

Solid-state NMR characterization of high-loading solid solutions of API and excipients formed by electrospinning.

Journal of pharmaceutical sciences 20120401

Central infusion of aliskiren prevents sympathetic hyperactivity and hypertension in Dahl salt-sensitive rats on high salt intake.

American journal of physiology. Regulatory, integrative and comparative physiology 20120401

Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.

The Journal of pharmacy and pharmacology 20120401

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.

European journal of heart failure 20120401

2-Cyano-2-methyl-propanamide.

Acta crystallographica. Section E, Structure reports online 20120401

Key advances in antihypertensive treatment.

Nature reviews. Cardiology 20120320

[Angio-oedema and medication that interferes with the renin-angiotensin-aldosterone system--a systematic review].

Ugeskrift for laeger 20120312

Addition of aliskiren to angiotensin II receptor blockers ameliorates renal tubular injury and reduces intima media thickness of carotid artery in patients with diabetic nephropathy.

International journal of cardiology 20120308

New roles for renin and prorenin in heart failure and cardiorenal crosstalk.

Heart failure reviews 20120301

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301

Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301

Spectrofluorimetric determination of aliskiren in tablets and spiked human plasma through derivatization with dansyl chloride.

Journal of fluorescence 20120301

Haemodynamic effects of aliskiren in decompensated severe heart failure.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301

Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.

British journal of pharmacology 20120301

Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.

Journal of cardiovascular pharmacology 20120301

Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury--beyond the direct renin inhibition.

Hypertension research : official journal of the Japanese Society of Hypertension 20120301

Aliskiren in patients with diabetes: a systematic review.

Current vascular pharmacology 20120301

Mechanistic insights into the antifibrotic activity of aliskiren in the kidney.

Hypertension research : official journal of the Japanese Society of Hypertension 20120301

Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients.

Journal of hypertension 20120301

Selective renin inhibition in obese hypertensive patients: perspectives from tissue penetration.

Journal of hypertension 20120301

Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.

International journal of clinical practice 20120301

Aliskiren for reninoma.

Nephrology (Carlton, Vic.) 20120301

Aliskiren: a potential antiarrhythmic drug?

Journal of clinical hypertension (Greenwich, Conn.) 20120301

Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120301

Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.

Expert review of cardiovascular therapy 20120301

Use of direct renin inhibitor in an HIV positive subject.

Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20120301

Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120201

Polycystic kidney disease presenting with hypertension and hypokalemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20120201

Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren.

European journal of heart failure 20120201

Reversibility of the effects of aliskiren in the renal versus systemic circulation.

Clinical journal of the American Society of Nephrology : CJASN 20120201

Aliskiren displays long-lasting interactions with human renin.

Naunyn-Schmiedeberg's archives of pharmacology 20120201

Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.

Therapeutic advances in cardiovascular disease 20120201

Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20120201

Current studies of diabetic cardiomyopathy and the advancement of our knowledge: time to learn from history, guidelines, ... and other disciplines?

European journal of heart failure 20120201

Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.

Current drug safety 20120201

In brief: aliskiren trial terminated.

The Medical letter on drugs and therapeutics 20120123

Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.

Hypertension research : official journal of the Japanese Society of Hypertension 20120101

Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension 20120101

Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents.

Hypertension research : official journal of the Japanese Society of Hypertension 20120101

Renal functional responses to selective intrarenal renin inhibition in Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension.

American journal of physiology. Renal physiology 20120101

Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats.

American journal of physiology. Regulatory, integrative and comparative physiology 20120101

Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg.

Current medical research and opinion 20120101

Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.

Journal of hypertension 20120101

Use of aliskiren in a 'real-life' model of hypertension management: analysis of national Web-based drug-monitoring system in Italy.

Journal of hypertension 20120101

Does the combination of a renin inhibitor with a statin have potential for improved inhibition of atherosclerosis?

Journal of hypertension 20120101

Assessing antihypertensive treatment by real life data.

Journal of hypertension 20120101

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.

BMJ (Clinical research ed.) 20120101

Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: structure/function studies towards the rational design of inhibitors.

PLoS pathogens 20120101

Efficacy of aliskiren in Japanese chronic kidney disease patients with hypertension.

Renal failure 20120101

Aliskiren-induced chyloperitoneum in a patient on peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20120101

Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension.

Journal of the American Society of Hypertension : JASH 20120101

Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension.

Journal of the American Society of Hypertension : JASH 20120101

Diabetic macular edema: current and emerging therapies.

Middle East African journal of ophthalmology 20120101

How full is our antihypertensives pipeline?

Journal of pharmacology & pharmacotherapeutics 20120101

What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative study.

BMC family practice 20120101

Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development.

Journal of postgraduate medicine 20120101

Targeting NADPH oxidases in vascular pharmacology.

Vascular pharmacology 20120101

[Recent advance in kidney and hypertension research].

Nihon Jinzo Gakkai shi 20120101

Lycium barbarum extracts protect the brain from blood-brain barrier disruption and cerebral edema in experimental stroke.

PloS one 20120101

Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.

Circulation journal : official journal of the Japanese Circulation Society 20120101

What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

Cardiovascular diabetology 20120101

Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients.

International journal of nephrology and renovascular disease 20120101

Emerging drug combinations to optimize renovascular protection and blood pressure goals.

International journal of nephrology and renovascular disease 20120101

Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction.

International journal of inflammation 20120101

Aliskiren prevents the toxic effects of peritoneal dialysis fluids during chronic dialysis in rats.

PloS one 20120101

Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

Cardiovascular magnetic resonance in systemic hypertension.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20120101

Different roles of mast cells in obesity and diabetes: lessons from experimental animals and humans.

Frontiers in immunology 20120101

Renin inhibitors inhibited the activity of recombinant human renin but not activity in healthy human plasma.

Clinical laboratory 20120101

Direct renin inhibition exerts an anti-hypertrophic effect associated with improved mitochondrial function in post-infarction heart failure in diabetic rats.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20120101

Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting.

Journal of asthma and allergy 20120101

Antioxidants in kidney diseases: the impact of bardoxolone methyl.

International journal of nephrology 20120101

Hyponatremia in a patient with scleroderma renal crisis: a potential role of activated renin-angiotensin system.

BMC nephrology 20120101

Does direct inhibition bring direct benefit?

Circulation journal : official journal of the Japanese Circulation Society 20120101

Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension.

Patient preference and adherence 20120101

Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.

Journal of the American Society of Hypertension : JASH 20120101

Aliskiren suppresses the renin-angiotensin-aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension.

International journal of nephrology and renovascular disease 20120101

Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20111201

Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20111201

Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.

Cardiovascular drugs and therapy 20111201

Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?

Journal of hypertension 20111201

Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.

Clinical drug investigation 20111201

Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.

Journal of clinical hypertension (Greenwich, Conn.) 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

[Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management].

Vnitrni lekarstvi 20111201

[Bartter syndrome: a new therapeutic approach].

Acta medica portuguesa 20111201

Aliskiren prevents hypertension and reduces asymmetric dimethylarginine in young spontaneously hypertensive rats.

European journal of pharmacology 20111130

Direct renin inhibition in a rat model of chronic allograft injury.

Transplantation 20111115

Limitations of targeting rate-limiting step of renin-angiotensin-aldosterone system in experimental chronic allograft nephropathy.

Transplantation 20111115

Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects.

Journal of clinical pharmacology 20111101

50 years of thiazides: should thiazide diuretics be considered third-line hypertension treatment?

American journal of therapeutics 20111101

Electromechanical effects of the direct renin inhibitor (aliskiren) on the pulmonary vein and atrium.

Basic research in cardiology 20111101

Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment.

Journal of hypertension 20111101

Atorvastatin reduces sympathetic activity in patients with chronic kidney disease.

Journal of hypertension 20111101

Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

European heart journal 20111101

Angioedema due to the renin inhibitor aliskiren (MAY 2011).

Cleveland Clinic journal of medicine 20111101

Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.

Postgraduate medicine 20111101

Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.

Pediatric nephrology (Berlin, Germany) 20111001

Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat.

Diabetologia 20111001

Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20111001

The role of direct renin inhibition in clinical practice: focus on combination therapy.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20111001

Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy.

Evidence-based medicine 20111001

Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion.

Hypertension (Dallas, Tex. : 1979) 20111001

A simple test to appreciate compliance to aliskiren treatment.

Journal of hypertension 20111001

Management of patients with chronic kidney disease.

Internal and emergency medicine 20111001

(R,R(Fc),S(Ru))-Chlorido(η-p-cymene){1-[1-(diphenyl-phosphanyl)ethyl]-2-[2-(diphenyl-phosphanyl)phenyl]ferrocene-κP,P'}ruthenium(II) hexa-fluorido-phosphate.

Acta crystallographica. Section E, Structure reports online 20111001

Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.

Journal of managed care pharmacy : JMCP 20111001

Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats.

Archives of medical science : AMS 20111001

Conformational analysis of aliskiren, a potent renin inhibitor, using high-resolution nuclear magnetic resonance and molecular dynamics simulations.

Journal of chemical information and modeling 20110926

Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20110901

Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110901

NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies.

Basic research in cardiology 20110901

Aliskiren affects fatty-acid uptake and lipid-related genes in rodent and human cardiomyocytes.

Biochemical pharmacology 20110901

Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.

Clinical and experimental pharmacology & physiology 20110901

What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?

Advances in therapy 20110901

Renin inhibitors.

Journal of clinical hypertension (Greenwich, Conn.) 20110901

Angiotensin receptor blockers: pharmacology, efficacy, and safety.

Journal of clinical hypertension (Greenwich, Conn.) 20110901

Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 20110901

Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints.

Heart (British Cardiac Society) 20110815

p90 ribosomal S6 kinase regulates activity of the renin-angiotensin system: a pathogenic mechanism for ischemia-reperfusion injury.

Journal of molecular and cellular cardiology 20110801

Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice.

The Journal of urology 20110801

Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.

Cardiovascular drugs and therapy 20110801

Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension.

Journal of clinical hypertension (Greenwich, Conn.) 20110801

Prevalence, Awareness, and Control of Hypertension among Diabetic Koreans.

Diabetes & metabolism journal 20110801

Synthesis, biological evaluation and docking studies of octane-carboxamide based renin inhibitors with extended segments toward S3' site of renin.

Bioorganic & medicinal chemistry 20110715

Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice.

Postgraduate medical journal 20110701

Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.

European journal of heart failure 20110701

Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.

European journal of heart failure 20110701

The ACQUIRE trial.

Expert opinion on pharmacotherapy 20110701

Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.

Journal of clinical hypertension (Greenwich, Conn.) 20110701

A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20110601

Direct renin inhibition: update on clinical investigations with aliskiren.

European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 20110601

Antiproteinuric response to add-on aliskiren in proteinuric patients treated with dual blockade of the renin-angiotensin system: a 12-month prospective uncontrolled study.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20110601

Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study.

Expert opinion on pharmacotherapy 20110601

Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues.

Therapeutic advances in cardiovascular disease 20110601

Possible involvement of the (pro)renin receptor-dependent system in the development of insulin resistance.

Frontiers in bioscience (Scholar edition) 20110601

Managing erectile dysfunction in hypertensive patients.

Journal of clinical hypertension (Greenwich, Conn.) 20110601

Aliskiren/amlodipine combination for the treatment of hypertension.

Drugs of today (Barcelona, Spain : 1998) 20110601

[A powerful duo: antihypertensives aliskiren and amlodipine in one tablet. Combination tablet for hypertensive patients with diabetes and overweight].

MMW Fortschritte der Medizin 20110512

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren.

British journal of clinical pharmacology 20110501

Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.

Reviews on recent clinical trials 20110501

Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials.

American journal of hypertension 20110501

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.

European heart journal 20110501

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.

Clinical journal of the American Society of Nephrology : CJASN 20110501

Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension.

The American journal of the medical sciences 20110501

Pharmacotherapy: inhibiting LV remodeling—the need for a targeted approach.

Nature reviews. Cardiology 20110501

Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control.

International journal of clinical practice 20110501

Hypertension treatment update: focus on direct renin inhibition.

Journal of the American Academy of Nurse Practitioners 20110501

Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.

Journal of clinical hypertension (Greenwich, Conn.) 20110501

[Advantages and limitations of renin inhibition with aliskiren].

Annales pharmaceutiques francaises 20110501

Initial combination therapy for treatment of hypertension.

Lancet (London, England) 20110430

Initial combination therapy for treatment of hypertension.

Lancet (London, England) 20110430

Initial combination therapy for treatment of hypertension.

Lancet (London, England) 20110430

In brief: Another three-drug combination for hypertension.

The Medical letter on drugs and therapeutics 20110404

Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110401

Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats.

Hypertension (Dallas, Tex. : 1979) 20110401

Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results.

Expert review of cardiovascular therapy 20110401

[Hypertension and hypokalemia - a reninoma as the cause of suspected liquorice-induced arterial hypertension].

Deutsche medizinische Wochenschrift (1946) 20110401

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.

Journal of human hypertension 20110301

Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.

Journal of clinical pharmacology 20110301

Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension 20110301

Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis.

American journal of hypertension 20110301

Are we ready to use aliskiren in children?

Pediatric nephrology (Berlin, Germany) 20110301

Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy.

Hypertension research : official journal of the Japanese Society of Hypertension 20110301

Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children.

Pediatric nephrology (Berlin, Germany) 20110301

Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study.

Journal of clinical hypertension (Greenwich, Conn.) 20110301

Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.

Journal of clinical pharmacology 20110201

Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats.

Human & experimental toxicology 20110201

Renin inhibition mitigates anti-angiogenesis in spontaneously hypertensive rats.

Journal of hypertension 20110201

Aliskiren in the treatment of hypertension and organ damage.

Cardiovascular therapeutics 20110201

Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy.

American journal of physiology. Renal physiology 20110201

Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.

International journal of clinical practice 20110201

Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.

Cardiovascular drugs and therapy 20110201

Determination of aliskiren in tablet dosage forms by a validated stability-indicating RP-LC method.

Journal of chromatographic science 20110201

Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema.

The American journal of medicine 20110201

Management of uncomplicated hypertension during pregnancy.

Prescrire international 20110201

Initial combination antihypertensives: let's ACCELERATE.

Lancet (London, England) 20110122

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.

Lancet (London, England) 20110122

Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment.

Expert opinion on drug metabolism & toxicology 20110101

Design and synthesis of potent macrocyclic renin inhibitors.

Bioorganic & medicinal chemistry letters 20110101

Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg.

Current medical research and opinion 20110101

Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).

European journal of heart failure 20110101

Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101

Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study).

International journal of clinical practice 20110101

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

European journal of heart failure 20110101

Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome.

International journal of nephrology 20110101

Aliskiren as an add-on treatment reduces albuminuria in patients with diabetes.

Nature reviews. Nephrology 20110101

The renin inhibitor aliskiren attenuates high-glucose induced extracellular matrix synthesis and prevents apoptosis in cultured podocytes.

Nephron. Experimental nephrology 20110101

Resistant hypertension workup and approach to treatment.

International journal of hypertension 20110101

Potential benefits of aliskiren beyond blood pressure reduction.

Cardiology in review 20110101

Regulation of vascular tone by adipocytes.

BMC medicine 20110101

Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension.

Journal of the American Society of Hypertension : JASH 20110101

Treatment options for hypertension in high-risk patients.

Vascular health and risk management 20110101

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.

Vascular health and risk management 20110101

Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.

BMJ (Clinical research ed.) 20110101

Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases.

Journal of biomedicine & biotechnology 20110101

[Salvage therapy with aliskiren in malignant familial hypertension in a breast-fed baby].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

Clinical utility of valsartan in the treatment of hypertension in children and adolescents.

Patient preference and adherence 20110101

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.

Vascular health and risk management 20110101

Treatment and landmark clinical trials for renoprotection.

Contributions to nephrology 20110101

Efficacy of aliskiren/hydrochlorothiazide combination for the treatment of hypertension: a meta-analytical approach.

The open cardiovascular medicine journal 20110101

[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].

Eksperimental'naia i klinicheskaia farmakologiia 20110101

Aliskiren: An orally active renin inhibitor.

Journal of pharmacy & bioallied sciences 20110101

Stroke, high blood pressure and the Renin-Angiotensin-aldosterone system - new developments.

Frontiers in pharmacology 20110101

Role of aliskiren in blood pressure control and renoprotection.

International journal of nephrology and renovascular disease 20110101

Multi-step usage of in vivo models during rational drug design and discovery.

International journal of molecular sciences 20110101

Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts.

Experimental diabetes research 20110101

Hypertension in chronic kidney disease: navigating the evidence.

International journal of hypertension 20110101

Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications.

International journal of hypertension 20110101

(Pro)renin Receptor in Kidney Development and Disease.

International journal of nephrology 20110101

Diabetic nephropathy - Epidemiology in Asia and the current state of treatment.

Indian journal of nephrology 20110101

Aliskiren: the first direct renin inhibitor available for clinical use.

Journal of nephrology 20110101

Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome.

Journal of the American Society of Hypertension : JASH 20110101

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor.

Therapeutics and clinical risk management 20110101

Long-term use and tolerability of irbesartan for control of hypertension.

Integrated blood pressure control 20110101

Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients.

Integrated blood pressure control 20110101

Validation of a therapeutic scheme for the treatment of resistant hypertension.

Journal of the American Society of Hypertension : JASH 20110101

Targeted therapies in diabetic nephropathy: an update.

Journal of nephrology 20110101

Role of natural herbs in the treatment of hypertension.

Pharmacognosy reviews 20110101

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

Vascular health and risk management 20110101

Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Fibrogenesis & tissue repair 20110101

Benefits of once-daily therapies in the treatment of hypertension.

Vascular health and risk management 20110101

Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors.

BMC bioinformatics 20110101

Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.

Journal of clinical pharmacology 20101201

Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.

Cardiovascular therapeutics 20101201

Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20101201

Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECS.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20101201

Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren.

Journal of cardiovascular pharmacology and therapeutics 20101201

Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.

Therapeutic advances in cardiovascular disease 20101201

Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.

Current medical research and opinion 20101201

Angiotensin II, tissue factor and the thrombotic paradox of hypertension.

Expert review of cardiovascular therapy 20101201

Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study.

Journal of clinical hypertension (Greenwich, Conn.) 20101201

Aliskiren/amlodipine (Tekamlo): another combination tablet for hypertension.

The Medical letter on drugs and therapeutics 20101129

Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.

Journal of human hypertension 20101101

A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.

American journal of physiology. Renal physiology 20101101

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.

Diabetes care 20101101

Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20101101

The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice.

Basic research in cardiology 20101101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20101101

Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension.

Drugs 20101022

[The role of direct inhibitors of renin].

Revue medicale suisse 20101020

Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.

Journal of hypertension 20101001

Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro.

Hypertension research : official journal of the Japanese Society of Hypertension 20101001

Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats.

American journal of physiology. Renal physiology 20101001

Aliskiren: beyond blood pressure reduction.

Expert opinion on investigational drugs 20101001

[New modalities of renin-angiotensin system inhibition: Renin inhibitors and active immunization against angiotensin II].

La Revue de medecine interne 20101001

Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.

Transplantation proceedings 20101001

Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.

Journal of clinical hypertension (Greenwich, Conn.) 20101001

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.

Journal of human hypertension 20100901

Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.

European journal of clinical pharmacology 20100901

Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression.

Current opinion in nephrology and hypertension 20100901

Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.

Clinical pharmacology and therapeutics 20100901

Of fads, fashion, surrogate endpoints and dual RAS blockade.

European heart journal 20100901

Progress toward novel treatments for chronic kidney disease.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20100901

Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context.

Clinical cardiology 20100901

[Antihypertensive drugs in 2010: old and new agents].

Revue medicale de Bruxelles 20100901

Mast cell degranulation mediates bronchoconstriction via serotonin and not via renin release.

European journal of pharmacology 20100825

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.

Diabetologia 20100801

Drug mechanisms to help in managing resistant hypertension in obesity.

Current hypertension reports 20100801

Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.

European heart journal 20100801

Novel therapeutic targets for hypertension.

Nature reviews. Cardiology 20100801

[Renal protection in the patients with idiopathic hypertensia: the possibilities of the combined blockade of the reninangiotensinaldosterone system].

Voenno-meditsinskii zhurnal 20100801

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Drugs 20100709

Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.

Journal of hypertension 20100701

Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.

Journal of hypertension 20100701

Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more.

Clinical research in cardiology : official journal of the German Cardiac Society 20100601

Aliskiren versus ramipril in hypertension.

Therapeutic advances in cardiovascular disease 20100601

Direct Renin inhibition: promising treatment in renoprotection?

Recent patents on cardiovascular drug discovery 20100601

New pharmacological treatments for improving renal outcomes in diabetes.

Nature reviews. Nephrology 20100601

Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR.

European journal of heart failure 20100601

Recent advances in tissue (pro)renin imaging.

Frontiers in bioscience (Elite edition) 20100601

The (pro)renin receptor and the mystic HRP--is there a role in cardiovascular disease?

Frontiers in bioscience (Elite edition) 20100601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100601

Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes.

American journal of hypertension 20100501

Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.

European journal of clinical pharmacology 20100501

Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension.

Current vascular pharmacology 20100501

Is there a future for direct renin inhibitors?

Expert opinion on investigational drugs 20100501

Unmet needs in managing hypertension: potential role of direct renin inhibition.

Postgraduate medicine 20100501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100501

Physiologic tailoring of treatment in resistant hypertension.

Current cardiology reviews 20100501

Total synthesis of 'aliskiren': the first Renin inhibitor in clinical practice for hypertension.

Organic letters 20100416

New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease.

Hypertension research : official journal of the Japanese Society of Hypertension 20100401

[The pharmacological profile and clinical findings on aliskiren (Rasilez tablet), direct renin inhibitor].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100401

Best strategies for hypertension management in type 2 diabetes and obesity.

Current diabetes reports 20100401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100401

Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats.

European journal of clinical investigation 20100401

Application of direct renin inhibition to chronic kidney disease.

Cardiovascular drugs and therapy 20100401

Aliskiren + hydrochlorothiazide.

Prescrire international 20100401

Current status of dual Renin Angiotensin aldosterone system blockade for the treatment of cardiovascular diseases.

The American journal of cardiology 20100315

Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.

American journal of physiology. Renal physiology 20100301

Blood pressure and diabetic nephropathy.

Diabetes care 20100301

[Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor aliskiren (RASANT)].

Medizinische Klinik (Munich, Germany : 1983) 20100301

The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.

Drugs of today (Barcelona, Spain : 1998) 20100301

Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Life sciences 20100227

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.

Journal of human hypertension 20100201

Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study.

Diabetes care 20100201

Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage.

Hypertension research : official journal of the Japanese Society of Hypertension 20100201

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Vnitrni lekarstvi 20100201

Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering.

Current diabetes reports 20100201

[Renal effects of combined anti-hypertensive treatments].

Recenti progressi in medicina 20100201

Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.

The Journal of the Association of Physicians of India 20100201

[Pharmacovigilance update].

Revue medicale suisse 20100120

Renin inhibition for hypertension: selecting the right role for a new class of drug.

American journal of therapeutics 20100101

The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?

Hypertension research : official journal of the Japanese Society of Hypertension 20100101

Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes.

Diabetologia 20100101

Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials.

Hypertension (Dallas, Tex. : 1979) 20100101

Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction.

Hypertension research : official journal of the Japanese Society of Hypertension 20100101

Successful applications of computer aided drug discovery: moving drugs from concept to the clinic.

Current topics in medicinal chemistry 20100101

Direct renin inhibition and the kidney.

Nature reviews. Nephrology 20100101

Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.

Expert review of cardiovascular therapy 20100101

[An experience with the use of direct renin inhibitor aliskiren in a patient with obesity and arterial hypertension].

Kardiologiia 20100101

Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.

Clinical drug investigation 20100101

Aliskiren: a new drug for an old problem.

Cardiovascular & hematological agents in medicinal chemistry 20100101

[Progress in hypertension and diabetes mellitus].

Revista espanola de cardiologia 20100101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100101

[Overview of the RAAS in renal damage and hypertension].

Nihon Jinzo Gakkai shi 20100101

[Recent clinical evidences of RAS inhibitors on chronic kidney diseases].

Nihon Jinzo Gakkai shi 20100101

The role of renin angiotensin system inhibition in kidney repair.

Fibrogenesis & tissue repair 20100101

Direct renin inhibitors as antihypertensive agents.

American journal of therapeutics 20100101

Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Orphanet journal of rare diseases 20100101

[Renin, prorenin, and the direct renin inhibitor aliskiren].

Casopis lekaru ceskych 20100101

Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats.

Physiological research 20100101

New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren.

Journal of pharmacological sciences 20100101

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Vascular health and risk management 20100101

Aliskiren and valsartan combination therapy for the management of hypertension.

Vascular health and risk management 20100101

New class of agents for treatment of hypertension: focus on direct renin inhibition.

Vascular health and risk management 20100101

[Renin inhibitors--new direction in the treatment of arterial hypertension].

Terapevticheskii arkhiv 20100101

Aliskiren in the management of hypertension.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes.

PloS one 20100101

First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.

Indian heart journal 20100101

Cardio classics revisited--focus on the role of candesartan.

Vascular health and risk management 20100101

Renovascular and renoprotective properties of telmisartan: clinical utility.

International journal of nephrology and renovascular disease 20100101

Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment.

International journal of nephrology and renovascular disease 20100101

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

International journal of nephrology and renovascular disease 20100101

Evidence-based approach for managing hypertension in type 2 diabetes.